Novavax share price today

(NVAX)

Novavax share price is $8.51 & ₹725.03 as on 25 Dec 2024, 2.30 'hrs' IST

$8.51

▲

-0.13

(-1.5%)

Market is closed - opens 8 PM, 26 Dec 2024

View live Novavax share price in Dollar and Rupees. Guide to invest in Novavax from India. Also see the sentimental analysis on Indian investors investing in Novavax. Get details on the Indian mutual funds that are investing in Novavax. Get Analyst recommendations and forecasts along with all the Novavax's financials.

Novavax share price movements

Today's Low: $8.46
Today's High: $8.64
$8.51
0.65%
Downside
Day's Volatility :2.08%
Upside
1.45%
52 Weeks Low: $3.53
52 Weeks High: $23.86
$8.51
58.49%
Downside
52 Weeks Volatility :85.2%
Upside
64.33%

Novavax Returns

Period	Novavax, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-29.93%	-9.0%	0.0%
6 Months	-33.67%	-4.6%	0.0%
1 Year	72.27%	3.0%	0.0%
3 Years	-94.61%	0.0%	-21.1%

Novavax Key Statistics

in dollars & INR

Previous Close	$8.64
Open	$8.66
Today's High	$8.635
Today's Low	$8.455
Market Capitalization	$1.4B
Today's Volume	$1.5M
52 Week High	$23.8599
52 Week Low	$3.5324
Revenue TTM	$885.2M
EBITDA	$-243.2M
Earnings Per Share (EPS)	$-2.18
Profit Margin	-32.18%
Quarterly Earnings Growth YOY	0.71%
Return On Equity TTM	-898.2%

How to invest in Novavax from India?

It is very easy for Indian residents to invest directly in Novavax from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Novavax stock in both Indian Rupees (INR) and US Dollars (USD). Search for Novavax or NVAX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Novavax or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Novavax shares which would translate to 0.100 fractional shares of Novavax as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Novavax, in just a few clicks!

Returns in Novavax for Indian investors in Rupees

Investment Value

₹1,00,000

Novavax investment value today

Current value as on today

₹1,74,506

Returns

₹74,506

(+74.51%)

Returns from Novavax Stock

₹72,267 (+72.27%)

Dollar Returns

₹2,239 (+2.24%)

Indian investors sentiment towards Novavax

-53.66%

Period: Sep 26, 2024 to Dec 25, 2024. Change in 30 Days versus previous period

Investment in Novavax from India has reduced in the last 30 days as on Dec 26, 2024. -53.66% less purchase transactions for Novavax in the last 30 days versus the previous period.

-3%

Period: Sep 26, 2024 to Dec 25, 2024. Change in 30 Days versus previous period

Search volume for Novavax on INDmoney from India has reduced in the last 30 days as on Dec 26, 2024. -3% less investors are searching Novavax in the last 30 days versus the previous period.

Global Institutional Holdings in Novavax

Vanguard Group Inc
9.63%
BlackRock Inc
7.40%
Shah Capital Management
6.13%
State Street Corp
4.80%
D. E. Shaw & Co LP
3.71%
Geode Capital Management, LLC
2.19%

Analyst Recommendation on Novavax

Buy

66%Buy

16%Hold

16%Sell

Based on 12 Wall street analysts offering stock ratings for Novavax(by analysts ranked 0 to 5 stars)

Based on 12 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Novavax

What analysts predicted

Upside of 88.01%

Current:

$8.51

Target:

$16.00

Insights on Novavax

Price Movement
In the last 1 year, NVAX stock has moved up by 68.5%
Decreasing Revenue
Revenue is down for the last 2 quarters, 415.48M → 84.51M (in $), with an average decrease of 79.7% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 162.38M → -121.3M (in $), with an average decrease of 174.7% per quarter
NVAX vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 25.2% return, outperforming this stock by 120.4%

Novavax Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$34.3M	↑ 9.98%
Net Income	$-184.7M	↑ 0.53%
Net Profit Margin	-538.81%	↑ 50.65%

	FY19	Y/Y Change
Revenue	$18.7M	↓ 45.57%
Net Income	$-130.1M	↓ 29.58%
Net Profit Margin	-697.15%	↓ 158.34%

	FY20	Y/Y Change
Revenue	$475.6M	↑ 2448.48%
Net Income	$-427.5M	↑ 228.59%
Net Profit Margin	-89.89%	↑ 607.26%

	FY21	Y/Y Change
Revenue	$1.1B	↑ 141.02%
Net Income	$-1.7B	↑ 307.89%
Net Profit Margin	-152.12%	↓ 62.23%

	FY22	Y/Y Change
Revenue	$1.6B	↑ 39.49%
Net Income	$-657.9M	↓ 62.27%
Net Profit Margin	-41.15%	↑ 110.97%

	FY23	Y/Y Change
Revenue	$983.7M	↓ 38.48%
Net Income	$-545.1M	↓ 17.16%
Net Profit Margin	-55.41%	↓ 14.26%

	Q2 FY23	Q/Q Change
Revenue	$424.4M	↑ 424.3%
Net Income	$58.0M	↓ 119.74%
Net Profit Margin	13.67%	↑ 376.74%

	Q3 FY23	Q/Q Change
Revenue	$22.1M	↓ 94.8%
Net Income	$-130.8M	↓ 325.44%
Net Profit Margin	-592.71%	↓ 606.38%

	Q4 FY23	Q/Q Change
Revenue	$291.3M	↑ 1220.44%
Net Income	$-178.4M	↑ 36.41%
Net Profit Margin	-61.23%	↑ 531.48%

	Q1 FY24	Q/Q Change
Revenue	$93.9M	↓ 67.79%
Net Income	$-147.6M	↓ 17.29%
Net Profit Margin	-157.21%	↓ 95.98%

	Q2 FY24	Q/Q Change
Revenue	$415.5M	↑ 342.69%
Net Income	$162.4M	↓ 210.05%
Net Profit Margin	39.08%	↑ 196.29%

	Q3 FY24	Q/Q Change
Revenue	$84.5M	↓ 79.66%
Net Income	$-121.3M	↓ 174.7%
Net Profit Margin	-143.53%	↓ 182.61%

	FY18	Y/Y Change
Profit	$34.3M	↑ 9.98%

	FY19	Y/Y Change
Profit	$-95.2M	↓ 377.59%

	FY20	Y/Y Change
Profit	$475.6M	↓ 599.68%

	FY21	Y/Y Change
Profit	$1.1B	↑ 141.02%

	FY22	Y/Y Change
Profit	$696.3M	↓ 39.26%

	FY23	Y/Y Change
Profit	$639.9M	↓ 8.1%

	Q2 FY23	Q/Q Change
Profit	$368.6M	↑ 686.62%

	Q3 FY23	Q/Q Change
Profit	$-76.9M	↓ 120.85%

	Q4 FY23	Q/Q Change
Profit	$142.5M	↓ 285.35%

	Q1 FY24	Q/Q Change
Profit	$45.0M	↓ 68.38%

	Q2 FY24	Q/Q Change
Profit	$379.4M	↑ 742.34%

	Q3 FY24	Q/Q Change
Profit	$23.9M	↓ 93.7%

	FY18	Y/Y Change
Operating Cash Flow	$-184.8M	↑ 33.26%
Investing Cash Flow	$28.6M	↓ 20.5%
Financing Cash Flow	$102.8M	↑ 59.29%

	FY19	Y/Y Change
Operating Cash Flow	$-136.6M	↓ 26.08%
Investing Cash Flow	$38.5M	↑ 34.61%
Financing Cash Flow	$98.4M	↓ 4.3%

	FY20	Y/Y Change
Operating Cash Flow	$-42.5M	↓ 68.86%
Investing Cash Flow	$-377.8M	↓ 1081.45%
Financing Cash Flow	$984.8M	↑ 900.94%

	FY21	Y/Y Change
Operating Cash Flow	$322.9M	↓ 859.14%
Investing Cash Flow	$100.2M	↓ 126.51%
Financing Cash Flow	$461.7M	↓ 53.11%

	FY22	Y/Y Change
Operating Cash Flow	$-415.9M	↓ 228.79%
Investing Cash Flow	$-93.0M	↓ 192.84%
Financing Cash Flow	$325.0M	↓ 29.61%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-171.9M	↓ 47.19%
Investing Cash Flow	$-7.8M	↑ 0.0%
Financing Cash Flow	$61.3M	↓ 117.31%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-39.7M	↓ 76.94%
Investing Cash Flow	$-18.4M	↑ 136.42%
Financing Cash Flow	$197.1M	↑ 221.38%

Novavax Technicals Summary

Sell

Neutral

Buy

Novavax is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Novavax Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Novavax, Inc.	-2.74%	-33.67%	72.27%	-94.61%	112.75%
Regeneron Pharmaceuticals, Inc.	-5.12%	-32.01%	-18.29%	12.56%	91.19%
Biontech Se	-3.72%	41.99%	6.11%	-55.22%	226.93%
Alnylam Pharmaceuticals, Inc.	-3.99%	-1.52%	23.75%	50.98%	112.09%
Vertex Pharmaceuticals Incorporated	-12.61%	-13.61%	0.03%	83.58%	86.41%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Novavax, Inc.	NA	NA	0.0	-1.43	-8.98	-0.11	NA	-3.29
Regeneron Pharmaceuticals, Inc.	17.67	17.67	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.06	0.51	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Novavax, Inc.	Buy	$1.4B	112.75%	NA	-32.18%
Regeneron Pharmaceuticals, Inc.	Buy	$78.5B	91.19%	17.67	33.61%
Biontech Se	Buy	$27.4B	226.93%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$31.4B	112.09%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$105.1B	86.41%	32.84	-4.51%

About Novavax

Novavax, Inc. is a biotechnology company focused on delivering novel products that effectively use innovative technology to solve known and emerging disease threats. The biotechnology giant is dedicated to creating cost-effective and democratized vaccine solutions for infectious diseases, such as seasonal flu, Ebola, COVID-19, and more. Founded in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland. It specializes in developing recombinant vaccines, and its lineup includes NVX-CoV2373, NanFlu, and ResVax, helpful in treating or preventing coronavirus, seasonal quadrivalent influenza, and a respiratory syncytial virus, respectively. Novavax, Inc. is also testing Matrix-M and its EBOV vaccine candidate in the Phase I clinical trial. It is also developing additional pre-clinical stage vaccine programs for occurrences such as MERS. It presently has over 750 employees, and its Nuvaxovid, a COVID-19 solution, is the fifth approved vaccine in the European Union. Further, Novavax has also filed the complete CMC data package with the FDA. It combines Novavax’s manufacturing prowess with Serum Institute of India Pvt. Ltd. (SII)’s experience for improved vaccine manufacturing. In addition, it also purchased Praha Vaccines and its vaccine factory in the Czech Republic, having a capacity of 1 billion doses per year. Currently Novavax, Inc. has a market cap of $1.83 Billion. It has a P.E ratio of -6.2. The shares of Novavax, Inc. are trading at $8.51. .

Organization	Novavax
Employees	1543
CEO	Mr. John Charles Jacobs M.B.A.
Industry	Health Technology

Management People of Novavax

Name	Title
Mr. John Charles Jacobs M.B.A.	President, CEO & Director
Mr. John Joseph Trizzino B.S., M.B.A.	President & COO
Mr. James Patrick Kelly C.F.A.	Executive VP, CFO & Treasurer
Mr. Mark Casey	Executive VP, Chief Legal Officer & Corporate Secretary
Mr. Richard P. Crowley	Executive VP & COO
Mr. Troy Morgan Esq., J.D.	Senior VP, Deputy General Counsel & Chief Compliance Officer
Ms. Erika S. Trahan	Associate Director of Investor & Public Relations
Mr. Ian J. Watkins	Executive VP & Chief Human Resources Officer
Ms. Silvia Taylor M.B.A.	Executive VP and Chief Corporate Affairs & Advocacy Officer
Dr. Robert Walker M.D.	Senior VP & Chief Medical Officer

Important FAQs about investing in Novavax from India :

What is Novavax share price today?

Novavax share price today stands at $8.51, Open: $8.66 ; Previous Close: $8.64 ; High: $8.64 ; Low: $8.46 ; 52 Week High: $23.86 ; 52 Week Low: $3.53. The stock opens at $8.66, after a previous close of $8.64. The stock reached a daily high of $8.64 and a low of $8.46, with a 52-week high of $23.86 and a 52-week low of $3.53.

Can Indians buy Novavax shares?

Yes, Indians can invest in the Novavax (NVAX) from India.

With INDmoney, you can buy Novavax at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Novavax at zero transaction cost.

How can I buy Novavax shares from India?

It is very easy to buy Novavax from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Novavax be purchased?

Yes, you can buy fractional shares of Novavax with INDmoney app.

What are the documents required to start investing in Novavax stocks?

To start investing in Novavax, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.